34 Chapter 1 intraepithelial neoplasia in women. N Engl J Med 2015; 372(8): 711-23. 74. Malagon T, Drolet M, Boily MC, Franco EL, Jit M, Brisson J, et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and metaanalysis. Lancet Infect Dis 2012; 12(10): 781-9. 75. Mesher D, Soldan K, Lehtinen M, Beddows S, Brisson M, Brotherton JM, et al. Population-Level Effects of Human Papillomavirus Vaccination Programs on Infections with Nonvaccine Genotypes. Emerg Infect Dis 2016; 22(10): 1732-40. 76. Vaccination coverage increases for second consecutive year, by 10% for HPV. https://www.rivm.nl/en/news/ vaccination-coverage-increases-forsecond-consecutive-year-by-10-forhpv17-06-2022). 77. RIVM. Bijna helft 9/10-jarigen haalt HPVvaccinatie bij eerste mogelijkheid. 2022. https://www.rivm.nl/nieuws/bijna-helft910-jarigen-haalt-hpv-vaccinatie-bijeerste-mogelijkheid (accessed 03-032023. 78. IKNL. Monitor bevolkingsonderzoek baarmoederhalskanker 2021. September 2022. https://www.rivm.nl/documenten/ monitor-bevolkingsonderzoekbaarmoederhalskanker-2021 (accessed 24-07 2023). 79. Gezondheidsraad. Advies Vaccinatie tegen HPV. 2019. 80. Vink MA, Bogaards JA, van Kemenade FJ, de Melker HE, Meijer CJ, Berkhof J. Clinical progression of high-grade cervical intraepithelial neoplasia: estimating the time to preclinical cervical cancer from doubly censored national registry data. Am J Epidemiol 2013; 178(7): 1161-9. 81. Bulk S, Van Kemenade FJ, Rozendaal L, Meijer CJ. The Dutch CISOE-A framework for cytology reporting increases efficacy of screening upon standardisation since 1996. J Clin Pathol 2004; 57(4): 388-93. 82. Sasieni P, Adams J, Cuzick J. Benefit of cervical screening at different ages: evidence from the UK audit of screening histories. Br J Cancer 2003; 89(1): 88-93. 83. Peto J, Gilham C, Fletcher O, Matthews FE. The cervical cancer epidemic that screening has prevented in the UK. Lancet 2004; 364(9430): 249-56. 84. Kitchener HC, Castle PE, Cox JT. Chapter 7: Achievements and limitations of cervical cytology screening. Vaccine 2006; 24 Suppl 3: S3/63-70. 85. Arbyn M, Raifu AO, Weiderpass E, Bray F, Anttila A. Trends of cervical cancer mortality in the member states of the European Union. Eur J Cancer 2009; 45(15): 2640-8. 86. van der Aa MA, Pukkala E, Coebergh JW, Anttila A, Siesling S. Mass screening programmes and trends in cervical cancer in Finland and the Netherlands. Int J Cancer 2008; 122(8): 1854-8. 87. Bulkmans NW, Berkhof J, Rozendaal L, van Kemenade FJ, Boeke AJ, Bulk S, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007; 370(9601): 1764-72. 88. Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007; 357(16): 157988. 89. Kitchener HC, Almonte M, Thomson C, Wheeler P, Sargent A, Stoykova B, et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol 2009; 10(7): 672-82. 90. Ronco G, Dillner J, Elfstrom KM, Tunesi S, Snijders PJ, Arbyn M, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials.
RkJQdWJsaXNoZXIy MjY0ODMw